Investor's Business Daily on MSN3mon
Monte Rosa Almost Doubles — Up 94% — On A Massive Deal With Novartis
Monte Rosa Therapeutics bounded higher on Monday, as shares nearly doubled on a deal with Novartis to develop treatments for ...
Nasdaq1mon
Monte Rosa downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo analyst Derek Archila downgraded Monte Rosa Therapeutics (GLUE) to Equal Weight from Overweight with a price arget of $11, down from $14. The firm thinks the stock’s upside is ...
Yahoo Finance27d
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
BOSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines ...